Publications by authors named "Kevin Bowrin"

Claim this Profile
H
High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Linda Fried, Niklas Schmedt, Kerstin Folkerts, Kevin Bowrin, Hanaya Raad

Nephrol Dial Transplant· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England.
Laura Portas, Rupert Bauersachs, Kevin Bowrin, Jean-Baptiste Briere, Alexander Cohen

Vasc Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
Carina Blomström Lundqvist, Sara Själander, Luis A Garcia Rodriguez, Örjan Åkerborg, Guanyi Jin, Kevin Bowrin

J Med Econ· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.
Olivia Wu, Stephen Morris, Torben Bjerregaard Larsen, Flemming Skjøth, Alex Evans, Kevin Bowrin

Cardiovasc Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.
Csaba Kovesdy, Niklas Schmedt, Kerstin Folkerts, Kevin Bowrin, Hanaya Raad

BMC Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.
Rupert Bauersachs, Olivia Wu, Neil Hawkins, Kevin Bowrin, Piotr Wojciechowski

Cardiovasc Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes.
Linda F Fried, Kerstin Folkerts, Beata Smeta, Kevin Deon Bowrin, Paul Mernagh

Am J Manag Care· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease.
Marc Schindewolf, Jan Beyer-Westendorf, Janita Balradj, Kevin Bowrin, Maria Huelsebeck

Angiology· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of real-world evidence in meta-analyses and cost-effectiveness models.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Mondher Toumi, Aurélie Millier

J Med Econ· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Martin R Cowie, André Lamy, Pierre Levy, Stuart Mealing, Aurélie Millier, Kevin Bowrin

Cardiovasc Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Rupert Bauersachs, Olivia Wu, Jean-Baptiste Briere, Kevin Bowrin, Katarzyna Borkowska

Cardiovasc Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Erkki Soini, Outi Virtanen, Saku Väätäinen, Jean-Baptiste Briere, Kevin Bowrin

Adv Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu

J Mark Access Health Policy· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015.
Varun Sundaram, Chloe Bloom, Rosita Zakeri, Julian Halcox, Alexander Cohen, Kevin Bowrin

Eur Heart J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review.
Rupert Bauersachs, Uwe Zeymer, Jean-Baptiste Brière, Caroline Marre, Kevin Bowrin

Cardiovasc Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease.
Rupert Bauersachs, Sebastian Debus, Mark Nehler, Maria Huelsebeck, Janita Balradj, Kevin Bowrin

Angiology· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Jean-Baptiste Briere, Olivia Wu, Kevin Bowrin, Aurélie Millier, Mondher Toumi

Curr Med Res Opin· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Jean-Baptiste Briere, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Piotr Wojciechowski

J Med Econ· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analyses using real-world data: an overview of the literature.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Emilie Clay

J Med Econ· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study.
Luca D Esposti, Jean-Baptiste Briere, Kevin Bowrin, Sangiorgi Diego, Valentina Perrone

Future Cardiol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Craig I Coleman, Jean-Baptiste Briere, Laurent Fauchier, Pierre Levy, Kevin Bowrin

J Mark Access Health Policy· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective.
Pierre Levy, David Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin

J Mark Access Health Policy· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
Jean-Baptiste Briere, Kevin Bowrin, Vanessa Taieb, Aurélie Millier, Mondher Toumi

Curr Med Res Opin· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis